Business Context and Reporting Period
This Form 6-K filing by IM Cannabis Corp. covers the month of August 2026. The report details a financing transaction executed on August 6, 2026, with closing on August 7, 2026. The Company, a foreign private issuer based in Israel, operates in the medical cannabis sector with a focus on Israel and Germany markets.
Key Financial Metrics
The filing discloses specific details regarding a new debt and equity financing instrument but does not provide consolidated revenue, profit, cash flow, or margin data for the period.
- Gross Proceeds: US$250,000 (Subscription Amount).
- Net Proceeds: US$225,000 (intended for general corporate purposes).
- Instrument Type: Convertible Note and Warrant.
- Interest Rate: 8.0% per annum (increases to 14.0% upon Event of Default).
- Repayment Terms: Not repayable in cash; obligations satisfied solely through share issuance upon conversion.
- Warrant Details: 2,052,545 shares exercisable at CAD$0.17 per share for 5 years.
Material Changes
The primary material change is the issuance of the convertible note and warrant. The filing does not provide comparative financial data against prior periods to quantify changes in revenue, debt levels, or liquidity ratios.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use net proceeds for general corporate purposes. Management has agreed to file a resale registration statement (Form F-3) within 30 trading days of the closing date.
Risks and Contingencies: The filing includes extensive forward-looking statement disclaimers citing significant risks, including:
- Regulatory compliance in highly regulated jurisdictions.
- Impact of war, conflict, and civil unrest in Eastern Europe and the Middle East, specifically the multi-front war in Israel.
- Reliance on third-party supply agreements and key personnel.
- Ability to maintain Nasdaq Capital Market listing requirements.
- Uncertainty regarding profitability and the ability to achieve growth objectives in Germany.
Investor Verification Checklist
- Verify the effective date of the Form F-3 resale registration statement to ensure investor liquidity.
- Confirm the current trading price of Common Shares relative to the Fixed Price (US$0.122) and Floor Price (US$0.02436) to assess potential dilution.
- Review the Company's latest Form 20-F for updated liquidity positions and debt obligations beyond this new note.
- Monitor operational impacts of the ongoing conflict in Israel on production and supply chains.
- Check for any subsequent filings regarding the 4-month trading lock-up period for the Warrant Shares.